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Class IA phosphatidylinositol-3 kinases (PI3Ks) togetherwith AKT and mammalian target of rapamycin (mTOR)
comprise the central axis of a complex, interconnected sig-
naling network that integrates signals from growth factors,
insulin, nutrients and oxygen to play a critical role in con-
trolling cell growth, proliferation, metabolism, survival, and
tumor angiogenesis. De-regulation of these processes is a
required hallmark of cancer1 and aberrant activation of the
class IA PI3K signaling occurs frequently in many malignan-
cies including non-small cell lung cancer (NSCLC).
The PI3K Family and Downstream Signaling
PI3Ks are lipid kinases that phosphorylate the 3-
hydoxyl group in phosphatidylinositol and phosphoinositi-
des.2 They are grouped into three classes based on structure
and substrate specificity: Class I PI3Ks convert phosphatidyl-
inositol-4,5-bisphosphate (PtdIns(4,5)P2) to phosphatidylino-
sitol-3,4,5-trisphosphate (PtdIns(3,4,5)P3). Class I PI3Ks are
subdivided into class IA PI3Ks which are predominantly
activated by growth factor receptor tyrosine kinases and class
IB PI3Ks which are activated by G protein coupled receptors.
Many studies have established a link between aberrant acti-
vation of class IA PI3Ks and oncogenesis.3–7 Class II PI3Ks
catalyze the production of PtdIns(3)P and PtdIns(3,4)P2 and
are important for clathrin mediated membrane trafficking.8
Class III consists of a single member, hVPS34 which produces
PtdIns(3)P and is involved in the regulation of vesicle traffick-
ing, activation of mTOR by amino acids and autophagy.9,10
Class IA PI3K, Subunits and Activation
Class IA PI3Ks are heterodimeric proteins that consist
of a p110 catalytic subunit and a p85 regulatory subunit.
There are three isoforms of the p110 catalytic subunit
(p110, p110, and p110) encoded by three genes PIK3CA,
PIK3CB, and PIK3CD. p110 and p110 are ubiquitously
expressed in normal and tumor tissue, while expression of
p110 is restricted to leukocytes. p110 is important for
growth factor and insulin signaling as well as for vascular
development and integrity.11–13 To date, only mutations in
PIK3CA have been commonly described in cancer.14,15
p110 (which may also be activated by G-protein coupled
receptors) is important for glucose metabolism, cell prolifer-
ation and drives oncogenic transformation in the context of
PTEN loss.16,17 The p85 regulatory subunit (present in several
isoforms: p85, p85, p55, p55, and p50) is crucial for
mediating the activation of class IA PI3Ks by receptor ty-
rosine kinases. It binds phosphorylated receptor tyrosine
kinases directly or via adapter proteins (such as IRS-1 or
Gab1) recruiting PI3K to its site of action at the cell mem-
brane and allowing activation of the p110 catalytic subunit
and rapid synthesis of PtsIns(3,4,5)P3. Activating mutations
in the gene encoding p85, PIK3R1, have been reported in
colon cancer and glioblastoma.18–20 Class IA PI3Ks bind and
may be directly activated by RAS.21,22
Inactivation of PI3K IA Signaling
The reaction catalyzed by class IA PI3Ks is directly antag-
onized by the lipid phosphatase PTEN which dephosphorylates the
3 position of PtdIns(3,4,5)P3 to produce PtdInsI(4,5)P2 or by the
Src-homology-2 containing phosphatases SHIP1 and SHIP2 which
dephosphorylate PtdIns(3,4,5)P3 to produce PtdIns(3,4)P2.23
The PI3K/AKT/mTOR Pathway
Generation of PtdIns(3,4,5)P3 within the cell membrane
by class IA PI3Ks initiates a signaling cascade (Figure 1) that
activates AKT and mTOR (the latter of which is present in two
multiprotein complexes mTORC1 and mTORC2, described be-
low). PtdIns(3,4,5)P3 binds the plekstrin homology domain of
the AKT (a family of highly homologous serine/thronine ki-
nases, AKT1, AKT2, and AKT3) localizing AKT to the cell
membrane. AKT1 is then phosphorylated at Thr308 (Thr309 in
AKT2 and Thr305 in AKT3) in the catalytic domain by PDK1,
another plekstrin homology domain containing colocalized ki-
nase24 and at Ser473 in the C-terminal hydrophobic motif (or
Ser474 in AKT2 and Ser472 in AKT3) by the mTORC2
complex.25 Activated AKT is released from the plasma mem-
*Department of Haematology and Medical Oncology, †Research Division,
Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne;
and ‡Department of Biochemistry and Molecular Biology, University of
Melbourne, Parkville, Victoria, Australia.
Disclosure: Dr. Solomon was paid an honorarium and travel expenses to
serve on an advisory committee of Novartis the company that manufac-
tures BE 2235. He has received research funding from Novartis as well.
Dr. Pearson declares no conflicts of interest.
Address for correspondence: Benjamin Solomon, MBBS, PhD, FRACP,
Department of Haematology and Medical Oncology, Peter MacCallum
Cancer Centre, Locked Bag 1, A’Beckett Street, Victoria 8006, Australia.
E-mail: ben.solomon@petermac.org
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0407-0787
Journal of Thoracic Oncology • Volume 4, Number 7, July 2009 787
brane and phosphorylates multiple nuclear and cytoplasmic
targets (over 100 putative AKT substrates have been reported
[www.phosphosite.org]) resulting in pleiotopic effects on
cellular homeostasis (Figure 1 and reviewed by Manning and
Cantley26). The phosphatase PHLPP inactivates AKT by
dephosphorylating AKT at Ser473.27
The effects of AKT on cell growth and metabolism are
mediated largely by activation of the mTORC1 complex which
acts as a master regulator of protein synthesis in response to
multiple inputs.28,29 mTORC1 contains mTOR complexed with
Raptor, PRAS40, and mLST8 and is sensitive to inhibition by
rapamycin and its analogues including RAD001 and CCI-779.28
mTOR also exists in a distinct complex termed mTORC2 where
it is combined with Rictor, mSIN1, Protor and mLST8.28,30 This
complex is resistant to rapamycin, lies upstream of AKT25 and
has other less well-characterized effects including regulation of
actin organization.31
Activation of mTORC1 by AKT involves phosphoryla-
tion of TSC2 (which exists in a complex with TSC1) leading to
accumulation of the GTP bound form of the GTPase RheB
which activates mTORC1. AKT also phosphorylates and inac-
tivates PRAS40, an inhibitory component of the mTORC1
complex.32 mTOR may be modulated by energy status via
LKB1/STK11 and AMPK,33 hypoxia through REDD1 signal-
ing34 and nutrient availability by hVPS3410 (Figure 1).
mTORC1 acts on substrates including p70 S6 kinase and eIF4E-
BP1 to influence translation of mRNA encoding key proteins
such as cyclin D1, MYC, and HIF-1. It also stimulates ribo-
some biogenesis and inhibits autophagy.35,36
Role of Cross-Talk and Feedback
The class IA PI3K/AKT/mTOR axis is a critical hub for
cross talk with co-operating pathways and negative feedback
loops within a complex and interconnected signaling envi-
ronment. It is intimately linked with the RAS/RAF/MAPK
pathway at its apex where RAS binds to and directly activates
class IA PI3K21 and through interactions between many
downstream components of each pathway.37 Indeed, the
p110 isoform is critical for RAS driven tumorigenesis and
inhibition of both PI3K and MEK seems critical for targeting
FIGURE 1. Signaling through the class IA phosphatidylinisitol-3 kinases/AKT/mammalian target of rapamycin (PI3K/AKT/
mTOR) axis integrates extracellular signals from insulin and growth factors together with energy status, oxygenation and nu-
trient availability to modulate processes including cell growth, survival, proliferation, glucose metabolism, and angiogenesis.
The topology of this signaling network, genetic alterations of components of the PI3K pathway in non-small cell lung cancer
(NSCLC) and presence of feedback loops (indicated by the broken red arrows) are described in the text.
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of KRAS driven lung tumors.22,38 There is also significant
cross talk with other pathways including the JNK and LKB1/
AMPK pathways.39,40 Adding further complexity is an exten-
sive and context dependent network of feedback loops (re-
viewed in Carracedo et al.41) that act as rheostats to maintain
exquisite control of the pathway in normal cells.
Genetic Alterations of the PI3K Pathway in
NSCLC
Phosphorylation of AKT is evident in 50 to 70% of
NSCLCs indicating that activation of class IA PI3K/AKT
signaling is a frequent event in this malignancy.42–44 Consti-
tutive PI3K activation may occur as a consequence of genetic
changes in upstream signaling components (e.g., EGFR muta-
tions or copy number gain and KRAS mutations), mutations or
amplification of PIK3CA, PTEN loss or activation of down-
stream elements of the pathway (summarized in Table 1).
Although activating mutations in PIK3CA have been
described in many human cancers45 and occur at high fre-
quency in breast (27%), colorectal (15%), and endometrial
cancer (24%),14,15 PIK3CA mutations occur in only about 3%
of NSCLC.14,46–49 However, increased copy number of the
PIK3CA gene is a more frequent event in NSCLC being
observed in 33% (46 of 139) of squamous cell carcinomas49
and 5.9% of adenocarcinomas (12 of 195)49 with high-level
copy number gains (fivefold) seen exclusively in squamous
cell carcinomas in multiple studies.48–51
Inactivating mutations or deletions of PTEN are un-
common in NSCLC (5%).52–54 However, reduced or absent
PTEN protein expression is frequent55 and may be explained
by promoter hypermethylation which is reported to occur in
25 to 40% of cases.55,56
Mutations in two downstream components of the class IA
PI3K/AKT/mTOR pathway have been described in NSCLC. An
uncommon activating mutation in the pleckstrin homology
domain of AKT1 (E17K), initially identified in breast, ovar-
ian, and colorectal cancers,57 has been described in about 1%
of NSCLC (with reported cases demonstrating squamous
histology).58–60 More common inactivating mutations in
LKB1/STK11 are seen in approximately 11% of NSCLC.
These mutations are more frequent in tumors from Cauca-
sians than Asians, adenocarcinomas and large cell carcino-
mas than squamous cell carcinomas and are associated with
smoking history and with KRAS mutations.61–66 Loss of
LKB1 has been shown to potently synergize with KRAS
mutations in lung tumorigenesis.67
Challenges in Targeting PI3K Signaling in Lung
Cancer
The first generation of PI3K inhibitors, wortmannin and
LY2994002, had preclinical antitumor activity, but suffered
from poor specificity,68,69 poor pharmacological properties
and toxicities that precluded their clinical use. Novel PI3K
inhibitors have been developed70,71 and join mTOR inhibitors
in the armamentarium of agents to target the PI3K pathway.
Clinical trials with SF-1126 (a prodrug of LY294002); PX-
866 (a pegylated wortmannin derivative); XL147, a selective
PI3K inhibitor; as well as BEZ235, BGT226, and XL765
(dual inhibitors of PI3K and mTOR) have been initiated
(www.clinicaltrials.gov). Of significance, the presence of
feedback and crosstalk within the circuitry of class IA PI3K/
AKT/mTOR signaling imply that maximal therapeutic effect
is likely require pathway inhibition at multiple levels and/or
inhibition of multiple pathways simultaneously. For example,
inhibition of mTORC1 by rapamycin analogues leads to
increased AKT activation demonstrable in some tumors72–74
due to a feedback loop where S6K1 phosphorylates and
transcriptionally represses IRS-1.75 Inhibition of mTORC1
may also lead to activation of the ERK-MAPK pathway via
a feedback loop involving S6K-IRS-1-PI3K-RAS.41 Indeed
agents that inhibit both PI3K and mTOR76,77 and combina-
tions of P13K inhibitors with MEK inhibitors38,78,79 have
proved to be promising therapeutic strategies in preclinical
models. Appreciation of the intricacies of this complex and
interconnected signaling network is required to develop clin-
ical strategies that effectively target class IA PI3K signaling
in NSCLC.
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